Your session is about to expire
← Back to Search
Post PRRT Diagnosed with t-MN (MDS or AML) for Acute Myeloid Leukemia (MDS & PRRT Trial)
Summary
This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Timeline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger